The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas

Rein Willemze, Lorenzo Cerroni, Werner Kempf, Emilio Berti, Fabio Facchetti, Steven H Swerdlow, Elaine S Jaffe, Rein Willemze, Lorenzo Cerroni, Werner Kempf, Emilio Berti, Fabio Facchetti, Steven H Swerdlow, Elaine S Jaffe

Abstract

Primary cutaneous lymphomas are a heterogeneous group of T- and B-cell lymphomas that present in the skin with no evidence of extracutaneous disease at the time of diagnosis. The 2005 World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) consensus classification has served as a golden standard for the diagnosis and classification of these conditions. In September 2018, an updated version of the WHO-EORTC was published in the fourth edition of the WHO Classification of Skin Tumours Blue Book. In this classification, primary cutaneous acral CD8+ T-cell lymphoma and Epstein-Barr virus positive (EBV+) mucocutaneous ulcer are included as new provisional entities, and a new section on cutaneous forms of chronic active EBV disease has been added. The term "primary cutaneous CD4+ small/medium T-cell lymphoma" was modified to "primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder" because of its indolent clinical behavior and uncertain malignant potential. Modifications have also been made in the sections on lymphomatoid papulosis, increasing the spectrum of histologic and genetic types, and primary cutaneous marginal zone lymphomas recognizing 2 different subtypes. Herein, the characteristic features of these new and modified entities as well as the results of recent molecular studies with diagnostic, prognostic, and/or therapeutic significance for the different types of primary cutaneous lymphomas are reviewed. An update of the frequency and survival of the different types of primary cutaneous lymphomas is provided.

Conflict of interest statement

Conflict-of-interest disclosure: R.W. is a member of the Scientific Advisory Board of Takeda. The remaining authors declare no competing financial interests.

© 2019 by The American Society of Hematology.

Figures

Figure 1.
Figure 1.
Sézary syndrome. Patient presenting with (A) erythroderma. (B) Band-like infiltrate of atypical lymphoid cells in superficial dermis with formation of intraepidermal (Pautrier) microabscesses. (C) Strong expression of CD279 (PD-1) by neoplastic T cells is a useful marker to differentiate Sézary syndrome from erythrodermic inflammatory dermatoses. Original magnification ×40 (B-C); hematoxylin and eosin (B) and immunoperoxidase (C) stain.
Figure 2.
Figure 2.
Cutaneous anaplastic large cell lymphoma presenting with multiple skin lesions on the right lower leg. (A) Part disappeared spontaneously. (B) Histologic examination shows a diffuse infiltrate of large anaplastic cells, which are positive for CD30 (C) and show cytoplasmic staining for ALK (D). Staging was negative; initially, an expectant policy was followed. Twelve months after diagnosis, the patient developed systemic disease with involvement of the lungs and bone marrow. Treatment with multiagent chemotherapy was unsuccessful and she died 18 months after diagnosis. Original magnification ×400 (B-D); hematoxylin and eosin (B) and immunoperoxidase (C-D) stain.
Figure 3.
Figure 3.
Primary cutaneous acral CD8+T-cell lymphoma. (A) Typical clinical presentation, with slowly progressive skin tumor on the right ear. (B) Diffuse proliferation of medium-sized pleomorphic cells in the dermis; the atypical cells strongly express CD8 (C) and TIA-1 (D). (E) CD68 shows a positive Golgi dot-like staining. Original magnification ×20 (B,E) and ×40 (C-D); hematoxylin and eosin (B) and immunoperoxidase (C-E) stain.
Figure 4.
Figure 4.
Primary cutaneous CD4+small/medium T-cell lymphoproliferative disorder. (A) Patient presenting with a tumor on the left cheek. (B) Detail of atypical dermal infiltrate showing a predominance of small/medium lymphoid cells and scattered large lymphoid cells, which express CD4 (C). (D) Expression of CD279/PD-1 by medium-sized to large atypical T cells, partly arranged in clusters. Original magnification ×200 (B,D) and ×40 (C); hematoxylin and eosin (B) and immunoperoxidase (C-D) stain.
Figure 5.
Figure 5.
Primary cutaneous diffuse large B-cell lymphoma, leg type. (A) Cohesive sheets of large transformed cells with prominent nucleoli. Strong expression of BCL2 (B), IgM (C), and MYC (D) may facilitate differentiation from PCFCL. Original magnification ×400 (A, hematoxylin and eosin stain) and ×200 (B-D, immunoperoxidase stain).

References

    1. Willemze R, Jaffe ES, Burg G, et al. . WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785.
    1. LeBoit PE, Burg G, Weedon D, Sarasin A. World Health Organization Classification of Tumours: Pathology and Genetics of Skin Tumours. Lyon, France: IARC Press; 2006.
    1. Swerdlow SH, Campo E, Harris NL, et al. . World Health Organization Classification of Tumours of Hematopoietic and Lymphoid Tissue. Revised 4th ed Lyon, France: IARC Press; 2017.
    1. Elder DE, Massi D, Scolyer RA, Willemze R. WHO Classification of Skin Tumours. 4th ed Lyon, France: IARC Press; 2018.
    1. van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol. 2002;138(2):191-198.
    1. Agar NS, Wedgeworth E, Crichton S, et al. . Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730-4739.
    1. Gerami P, Rosen S, Kuzel T, Boone SL, Guitart J. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. Arch Dermatol. 2008;144(6):738-746.
    1. Wieser I, Wang C, Alberti-Violetti S, et al. . Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides. Arch Dermatol Res. 2017;309(6):453-459.
    1. van Santen S, Roach RE, van Doorn R, et al. . Clinical staging and prognostic factors in folliculotropic mycosis fungoides. JAMA Dermatol. 2016;152(9):992-1000.
    1. Hodak E, Amitay-Laish I, Atzmony L, et al. . New insights into folliculotropic mycosis fungoides (FMF): a single-center experience. J Am Acad Dermatol. 2016;75(2):347-355.
    1. van Santen S, van Doorn R, Neelis KJ, et al. . Recommendations for treatment in folliculotropic mycosis fungoides: report of the Dutch Cutaneous Lymphoma Group. Br J Dermatol. 2017;177(1):223-228.
    1. Klemke CD, Booken N, Weiss C, et al. . Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases. Br J Dermatol. 2015;173(1):93-105.
    1. Cetinözman F, Jansen PM, Vermeer MH, Willemze R. Differential expression of programmed death-1 (PD-1) in Sézary syndrome and mycosis fungoides. Arch Dermatol. 2012;148(12):1379-1385.
    1. Hurabielle C, Thonnart N, Ram-Wolff C, et al. . Usefulness of KIR3DL2 to diagnose, follow-up, and manage the treatment of patients with Sézary syndrome. Clin Cancer Res. 2017;23(14):3619-3627.
    1. Michel L, Jean-Louis F, Begue E, Bensussan A, Bagot M. Use of PLS3, Twist, CD158k/KIR3DL2, and NKp46 gene expression combination for reliable Sézary syndrome diagnosis. Blood. 2013;121(8):1477-1478.
    1. Boonk SE, Zoutman WH, Marie-Cardine A, et al. . Evaluation of immunophenotypic and molecular biomarkers for Sézary syndrome using standard operating procedures: a multicenter study of 59 patients. J Invest Dermatol. 2016;136(7):1364-1372.
    1. Elenitoba-Johnson KS, Wilcox R. A new molecular paradigm in mycosis fungoides and Sézary syndrome. Semin Diagn Pathol. 2017;34(1):15-21.
    1. Chevret E, Merlio JP. Sézary syndrome: translating genetic diversity into personalized medicine. J Invest Dermatol. 2016;136(7):1319-1324.
    1. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. . Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95(12):3653-3661.
    1. Kempf W, Pfaltz K, Vermeer MH, et al. . EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15):4024-4035.
    1. Saggini A, Gulia A, Argenyi Z, et al. . A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases. Am J Surg Pathol. 2010;34(8):1168-1175.
    1. Kempf W, Kazakov DV, Schärer L, et al. . Angioinvasive lymphomatoid papulosis: a new variant simulating aggressive lymphomas. Am J Surg Pathol. 2013;37(1):1-13.
    1. Kempf W. A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders. Semin Diagn Pathol. 2017;34(1):22-35.
    1. Karai LJ, Kadin ME, Hsi ED, et al. . Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. Am J Surg Pathol. 2013;37(8):1173-1181.
    1. Parrilla Castellar ER, Jaffe ES, Said JW, et al. . ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124(9):1473-1480.
    1. Kadin ME, Pinkus JL, Pinkus GS, et al. . Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative. Am J Surg Pathol. 2008;32(9):1421-1426.
    1. Oschlies I, Lisfeld J, Lamant L, et al. . ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study. Haematologica. 2013;98(1):50-56.
    1. Quintanilla-Martinez L, Jansen PM, Kinney MC, Swerdlow SH, Willemze R. Non-mycosis fungoides cutaneous T-cell lymphomas: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol. 2013;139(4):491-514.
    1. Attygalle AD, Cabeçadas J, Gaulard P, et al. . Peripheral T-cell and NK-cell lymphomas and their mimics; taking a step forward - report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology. 2014;64(2):171-199.
    1. Wada DA, Law ME, Hsi ED, et al. . Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol. 2011;24(4):596-605.
    1. Xing X, Feldman AL. Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous. Adv Anat Pathol. 2015;22(1):29-49.
    1. Onaindia A, Montes-Moreno S, Rodríguez-Pinilla SM, et al. . Primary cutaneous anaplastic large cell lymphomas with 6p25.3 rearrangement exhibit particular histological features. Histopathology. 2015;66(6):846-855.
    1. Vasmatzis G, Johnson SH, Knudson RA, et al. . Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood. 2012;120(11):2280-2289.
    1. Schrader AM, Chung YY, Jansen PM, et al. . No TP63 rearrangements in a selected group of primary cutaneous CD30+ lymphoproliferative disorders with aggressive clinical course. Blood. 2016;128(1):141-143.
    1. Velusamy T, Kiel MJ, Sahasrabuddhe AA, et al. . A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. Blood. 2014;124(25):3768-3771.
    1. Nicolae-Cristea AR, Benner MF, Zoutman WH, et al. . Diagnostic and prognostic significance of CDKN2A/CDKN2B deletions in patients with transformed mycosis fungoides and primary cutaneous CD30-positive lymphoproliferative disease. Br J Dermatol. 2015;172(3):784-788.
    1. Massone C, Crisman G, Kerl H, Cerroni L. The prognosis of early mycosis fungoides is not influenced by phenotype and T-cell clonality. Br J Dermatol. 2008;159(4):881-886.
    1. Rodríguez-Pinilla SM, Ortiz-Romero PL, Monsalvez V, et al. . TCR-γ expression in primary cutaneous T-cell lymphomas. Am J Surg Pathol. 2013;37(3):375-384.
    1. Kimura H, Ito Y, Kawabe S, et al. . EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood. 2012;119(3):673-686.
    1. Tokura Y, Ishihara S, Tagawa S, Seo N, Ohshima K, Takigawa M. Hypersensitivity to mosquito bites as the primary clinical manifestation of a juvenile type of Epstein-Barr virus-associated natural killer cell leukemia/lymphoma. J Am Acad Dermatol. 2001;45(4):569-578.
    1. Rodríguez-Pinilla SM, Barrionuevo C, Garcia J, et al. . EBV-associated cutaneous NK/T-cell lymphoma: review of a series of 14 cases from peru in children and young adults. Am J Surg Pathol. 2010;34(12):1773-1782.
    1. Iwatsuki K, Xu Z, Takata M, et al. . The association of latent Epstein-Barr virus infection with hydroa vacciniforme. Br J Dermatol. 1999;140(4):715-721.
    1. Sangueza M, Plaza JA. Hydroa vacciniforme-like cutaneous T-cell lymphoma: clinicopathologic and immunohistochemical study of 12 cases. J Am Acad Dermatol. 2013;69(1):112-119.
    1. Barrionuevo C, Anderson VM, Zevallos-Giampietri E, et al. . Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol. 2002;10(1):7-14.
    1. Kawa K, Okamura T, Yagi K, Takeuchi M, Nakayama M, Inoue M. Mosquito allergy and Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease. Blood. 2001;98(10):3173-3174.
    1. Petrella T, Maubec E, Cornillet-Lefebvre P, et al. . Indolent CD8-positive lymphoid proliferation of the ear: a distinct primary cutaneous T-cell lymphoma? Am J Surg Pathol. 2007;31(12):1887-1892.
    1. Greenblatt D, Ally M, Child F, et al. . Indolent CD8(+) lymphoid proliferation of acral sites: a clinicopathologic study of six patients with some atypical features. J Cutan Pathol. 2013;40(2):248-258.
    1. Li JY, Guitart J, Pulitzer MP, et al. . Multicenter case series of indolent small/medium-sized CD8+ lymphoid proliferations with predilection for the ear and face. Am J Dermatopathol. 2014;36(5):402-408.
    1. Wobser M, Roth S, Reinartz T, Rosenwald A, Goebeler M, Geissinger E. CD68 expression is a discriminative feature of indolent cutaneous CD8-positive lymphoid proliferation and distinguishes this lymphoma subtype from other CD8-positive cutaneous lymphomas. Br J Dermatol. 2015;172(6):1573-1580.
    1. Alberti-Violetti S, Fanoni D, Provasi M, Corti L, Venegoni L, Berti E. Primary cutaneous acral CD8 positive T-cell lymphoma with extra-cutaneous involvement: a long-standing case with an unexpected progression. J Cutan Pathol. 2017;44(11):964-968.
    1. Rodríguez Pinilla SM, Roncador G, Rodríguez-Peralto JL, et al. . Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers. Am J Surg Pathol. 2009;33(1):81-90.
    1. Cetinözman F, Jansen PM, Willemze R. Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma. Am J Surg Pathol. 2012;36(1):109-116.
    1. Balagué O, Martínez A, Colomo L, et al. . Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features. Am J Surg Pathol. 2007;31(9):1310-1322.
    1. Beltraminelli H, Leinweber B, Kerl H, Cerroni L. Primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases. Am J Dermatopathol. 2009;31(4):317-322.
    1. Garcia-Herrera A, Colomo L, Camós M, et al. . Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome. J Clin Oncol. 2008;26(20):3364-3371.
    1. Grogg KL, Jung S, Erickson LA, McClure RF, Dogan A. Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior. Mod Pathol. 2008;21(6):708-715.
    1. Senff NJ, Hoefnagel JJ, Jansen PM, et al. . Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol. 2007;25(12):1581-1587.
    1. Servitje O, Muniesa C, Benavente Y, et al. . Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients. J Am Acad Dermatol. 2013;69(3):357-365.
    1. van Maldegem F, van Dijk R, Wormhoudt TA, et al. . The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment. Blood. 2008;112(8):3355-3361.
    1. Edinger JT, Kant JA, Swerdlow SH. Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets. Am J Surg Pathol. 2010;34(12):1830-1841.
    1. Swerdlow SH. Cutaneous marginal zone lymphomas. Semin Diagn Pathol. 2017;34(1):76-84.
    1. Rijlaarsdam U, Bakels V, van Oostveen JW, et al. . Demonstration of clonal immunoglobulin gene rearrangements in cutaneous B-cell lymphomas and pseudo-B-cell lymphomas: differential diagnostic and pathogenetic aspects. J Invest Dermatol. 1992;99(6):749-754.
    1. Nihal M, Mikkola D, Horvath N, et al. . Cutaneous lymphoid hyperplasia: a lymphoproliferative continuum with lymphomatous potential. Hum Pathol. 2003;34(6):617-622.
    1. Grange F, Beylot-Barry M, Courville P, et al. . Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol. 2007;143(9):1144-1150.
    1. Kodama K, Massone C, Chott A, Metze D, Kerl H, Cerroni L. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood. 2005;106(7):2491-2497.
    1. Koens L, Vermeer MH, Willemze R, Jansen PM. IgM expression on paraffin sections distinguishes primary cutaneous large B-cell lymphoma, leg type from primary cutaneous follicle center lymphoma. Am J Surg Pathol. 2010;34(7):1043-1048.
    1. Lucioni M, Berti E, Arcaini L, et al. . Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers. Cancer Med. 2016;5(10):2740-2755.
    1. Schrader AMR, Jansen PM, Vermeer MH, Kleiverda JK, Vermaat JSP, Willemze R. High incidence and clinical significance of MYC rearrangements in primary cutaneous diffuse large B-cell lymphoma, leg type. Am J Surg Pathol. 2018;42(11):1488-1494.
    1. Senff NJ, Zoutman WH, Vermeer MH, et al. . Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol. 2009;129(5):1149-1155.
    1. Pham-Ledard A, Beylot-Barry M, Barbe C, et al. . High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type. JAMA Dermatol. 2014;150(11):1173-1179.
    1. Pham-Ledard A, Prochazkova-Carlotti M, Andrique L, et al. . Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. Mod Pathol. 2014;27(3):402-411.
    1. Koens L, Zoutman WH, Ngarmlertsirichai P, et al. . Nuclear factor-κB pathway-activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type. J Invest Dermatol. 2014;134(1):290-292.
    1. Zhou XA, Louissaint A Jr, Wenzel A, et al. . Genomic analyses identify recurrent alterations in immune evasion genes in diffuse large B-cell lymphoma, leg type. J Invest Dermatol. 2018;138(11):2365-2376.
    1. Dijkman R, Tensen CP, Jordanova ES, et al. . Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. J Clin Oncol. 2006;24(2):296-305.
    1. Menguy S, Gros A, Pham-Ledard A, et al. . MYD88 somatic mutation is a diagnostic criterion in primary cutaneous large B-cell lymphoma. J Invest Dermatol. 2016;136(8):1741-1744.
    1. Hope CB, Pincus LB. Primary cutaneous B-cell lymphomas with large cell predominance-primary cutaneous follicle center lymphoma, diffuse large B-cell lymphoma, leg type and intravascular large B-cell lymphoma. Semin Diagn Pathol. 2017;34(1):85-98.
    1. Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES. EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol. 2010;34(3):405-417.
    1. Koens L, Senff NJ, Vermeer MH, Willemze R, Jansen PM. Methotrexate-associated B-cell lymphoproliferative disorders presenting in the skin: A clinicopathologic and immunophenotypical study of 10 cases. Am J Surg Pathol. 2014;38(7):999-1006.
    1. Hoshida Y, Xu JX, Fujita S, et al. . Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007;34(2):322-331.
    1. Swerdlow SH, Quintanilla-Martinez L, Willemze R, Kinney MC. Cutaneous B-cell lymphoproliferative disorders: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol. 2013;139(4):515-535.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera